Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Candel Therapeutics stock
Learn how to easily invest in Candel Therapeutics stock.
Candel Therapeutics is a biotechnology business based in the US. Candel Therapeutics shares (CADL) are listed on the NASDAQ and all prices are listed in US Dollars. Candel Therapeutics employs 65 staff and has a trailing 12-month revenue of around $125,000.
How to buy Candel Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – CADL. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Candel Therapeutics stock price (NASDAQ: CADL)Use our graph to track the performance of CADL stocks over time.
Candel Therapeutics shares at a glance
|Latest market close||$2.36|
|52-week range||$1.40 - $6.75|
|50-day moving average||$1.80|
|200-day moving average||$3.06|
|Wall St. target price||$11.60|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.03|
Buy Candel Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Candel Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Candel Therapeutics price performance over time
|1 week (2023-01-19)||4.67%|
|1 month (2022-12-27)||59.12%|
|3 months (2022-10-27)||17.75%|
|6 months (2022-07-27)||-30.74%|
|1 year (2022-01-27)||-51.04%|
|2 years (2021-01-23)||N/A|
|3 years (2020-01-23)||N/A|
|5 years (2018-01-23)||N/A|
Is Candel Therapeutics stock undervalued or overvalued?
Valuing Candel Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Candel Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Candel Therapeutics's P/E ratio
Candel Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 75x. In other words, Candel Therapeutics shares trade at around 75x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Candel Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Candel Therapeutics financials
|Gross profit TTM||$125,000|
|Return on assets TTM||-23.35%|
|Return on equity TTM||-21.05%|
|Market capitalisation||$65 million|
TTM: trailing 12 months
Candel Therapeutics share dividends
We're not expecting Candel Therapeutics to pay a dividend over the next 12 months.
Candel Therapeutics overview
Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc.
Candel Therapeutics in the news
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
Frequently asked questionsWhat percentage of Candel Therapeutics is owned by insiders or institutions?
Currently 34.624% of Candel Therapeutics shares are held by insiders and 21.825% by institutions. How many people work for Candel Therapeutics?
Latest data suggests 65 work at Candel Therapeutics. When does the fiscal year end for Candel Therapeutics?
Candel Therapeutics's fiscal year ends in December. Where is Candel Therapeutics based?
Candel Therapeutics's address is: 117 Kendrick Street, Needham, MA, United States, 02494 What is Candel Therapeutics's ISIN number?
Candel Therapeutics's international securities identification number is: US1374041093
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert